Indian stocks: Visit www.stage2stocks.com →

NeuroSense Therapeutics Ltd.

Stage 4 · Declining · week 15

As of Oct 22, 2026, NeuroSense Therapeutics is in Stage 4, the downtrend phase, now in week 15 (since Jul 14, 2026). It closed at $2.44, 90.2% below its 52-week high and below its 200-day average, which is falling.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. More about the company

$2.44
-7.22% today
$4.6M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NRSN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 17w
S4 24w
S4 14w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 17w → S1 11w → S2 10w → S3 10w → S4 9w → S1 8w → S2 1w → S1 1w → S4 4w → S3 4w → S4 1w → S3 2w → S2 4w → S3 5w → S4 3w → S1 1w → S2 12w → S3 5w → S4 24w → S1 1w → S4 13w → S1 3w → S4 14w current
Total tracked: 165 weeks across 23 stage runs.

NRSN among Biotechnology511th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…511NRSNStage 4 · wk 157−67.0%
vs 52W High
-90.2%
$2.39 lo$24.80 hi
90.2% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 15
1w13w26w
Week 15, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-81.8%
200 DMA: $13.40 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.74x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-67.0%
3M
-79.7%
6M
-82.9%
YTD
-84.4%
1Y
-90.2%
Scan Membership
Breakout Watch
Latest: 2025-05-28
6 appearances in last 60 days. First seen: 2023-04-20.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 15 · Vol 0.74x
2026-10-21S4
Wk 15 · Vol 0.43x
2026-10-20S4
Wk 14 · Vol 0.55x
2026-10-19S4
Wk 14 · Vol 5.15x
2026-10-16S4
Wk 14 · Vol 0.42x
2026-10-15S4
Wk 14 · Vol 0.51x
2026-10-14S4
Wk 14 · Vol 1.37x
2026-10-13S4
Wk 13 · Vol 1.94x
2026-10-12S4
Wk 13 · Vol 0.30x
2026-10-09S4
Wk 13 · Vol 0.64x
2026-10-08S4
Wk 13 · Vol 0.63x
2026-10-07S4
Wk 13 · Vol 0.50x
Moving averages & range
50 DMA
$6.15
200 DMA
$13.40
52W High
$24.80
52W Low
$2.39
5D Low
$2.39
Resistance levels (recent highs)
20d High
$6.95
60d High
$10.84
120d High
$19.00
250d High
$24.80
Next resistance
+184.8%
to 20d High
ROE
-2175.0%
Profit margin 0.0%
Dividend Yield
0.00%
P/B -2.5

NeuroSense Therapeutics: quick answers

What stage is NeuroSense Therapeutics in?

As of Oct 22, 2026, NeuroSense Therapeutics (NRSN) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 14, 2026 and is in week 15. What the four stages mean

Is NeuroSense Therapeutics in an uptrend?

No. NeuroSense Therapeutics is in a Stage 4 downtrend. It trades 81.8% below its 200-day average, which is falling.

How far is NeuroSense Therapeutics from its 52-week high?

NeuroSense Therapeutics closed at $2.44 on Oct 22, 2026, 90.2% below its 52-week high of $24.80. Its 52-week low is $2.39.

How has NeuroSense Therapeutics performed over the past year?

As of Oct 22, 2026, NeuroSense Therapeutics is down 90.2% over the past year and down 84.4% so far in 2026.

Which sector and industry is NeuroSense Therapeutics in?

NeuroSense Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.